JP2008535798A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535798A5
JP2008535798A5 JP2008500972A JP2008500972A JP2008535798A5 JP 2008535798 A5 JP2008535798 A5 JP 2008535798A5 JP 2008500972 A JP2008500972 A JP 2008500972A JP 2008500972 A JP2008500972 A JP 2008500972A JP 2008535798 A5 JP2008535798 A5 JP 2008535798A5
Authority
JP
Japan
Prior art keywords
hematocrit
dose
weekly
hemoglobin
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535798A (ja
JP5737826B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/008620 external-priority patent/WO2006099154A1/en
Publication of JP2008535798A publication Critical patent/JP2008535798A/ja
Publication of JP2008535798A5 publication Critical patent/JP2008535798A5/ja
Application granted granted Critical
Publication of JP5737826B2 publication Critical patent/JP5737826B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008500972A 2005-03-11 2006-03-10 Ｖｅｇｆの阻害による貧血の処置 Expired - Fee Related JP5737826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66063805P 2005-03-11 2005-03-11
US60/660,638 2005-03-11
PCT/US2006/008620 WO2006099154A1 (en) 2005-03-11 2006-03-10 Treating anemia by inhibition of vegf

Publications (3)

Publication Number Publication Date
JP2008535798A JP2008535798A (ja) 2008-09-04
JP2008535798A5 true JP2008535798A5 (enExample) 2012-11-01
JP5737826B2 JP5737826B2 (ja) 2015-06-17

Family

ID=36676448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500972A Expired - Fee Related JP5737826B2 (ja) 2005-03-11 2006-03-10 Ｖｅｇｆの阻害による貧血の処置

Country Status (6)

Country Link
US (1) US7351411B2 (enExample)
EP (1) EP1855708A1 (enExample)
JP (1) JP5737826B2 (enExample)
AU (1) AU2006223314A1 (enExample)
CA (1) CA2598452A1 (enExample)
WO (1) WO2006099154A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3170005T (pt) 2014-07-18 2019-07-16 Sanofi Sa Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
AUPQ592100A0 (en) 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy

Similar Documents

Publication Publication Date Title
JP2008535798A5 (enExample)
JP2008532951A5 (enExample)
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
JP2010285439A5 (enExample)
IL190227A (en) Phenyl derivatives - [1,2,4] - oxadiazole - 5 - On with a phenyl group, their use in medicine, pharmaceuticals containing them, and a process for preparing the pharmaceutical preparations
WO2006050250A3 (en) Dose forms comprising vx-950 and their dosage regimen
WO2008012553A3 (en) Rake with pre-filter
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
ITTO20050525A1 (it) Lembi perfezionati per ridurre gli effetti dannosi dei detriti.
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2010005565A3 (en) Method of treating glycogen storage disease
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2007143548A3 (en) Myxoma virus mutants for cancer treatment
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution